Health Blueprint

Back to Longevity News

News summary

Viking Therapeutics Announces Closing of Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes, Including Full Exercise of Underwriters

Source: PR Newswire • Published: 28 Sept 2026, 20:30

Summarized by Masters of Longevity from PR Newswire.

Viking’s financing update: a news release about a biopharma company completing upsized stock and convertible note offerings to fund its metabolic drug programs.

Viking Therapeutics Announces Closing of Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes, Including Full Exercise of Underwriters
Key Takeaways
  • The company completed offerings raising approximately $575.0 million gross and about $547.8 million net proceeds.
  • Underwriters fully exercised overallotment options for both common stock and $33.75 million of convertible notes.
  • Proceeds are earmarked to advance VK2735 and VK3019 clinical programs and for general R&D and corporate purposes.
Read the full article at PR Newswire ↗

Continue exploring

Recommended MoL Picks

MoL PickCan Exergaming Improve Balance? What Older Adults Should KnowMotion-controlled games may make balance practice easier to repeat. The evidence supports a structured adjunct—not a fall-proofing shortcut.MoL PickSemaglutide Extended Lifespan in Mice. What Would Make It a Human Longevity Drug?A new animal study sharpens an important question: when do benefits in a particular disease become evidence for a longer, healthier life?MoL PickThe Next Obesity-Drug Race Is About What Weight You LoseRegeneron’s myostatin and activin A antibodies point to a sharper question for the GLP-1 era: not whether people can lose more weight, but whether medicine can preserve the tissue that makes weight loss healthier.